Listen
Reason for request
Inclusion
-
Clinical Benefit
| Moderate |
The actual benefit of MABELIO 500 mg is : - moderate in the indication "treatment in adults of hospital-acquired pneumonia, excluding ventilator-associated pneumonia" |
| Insufficient |
- insufficient in the indication "treatment in adults of community-acquired pneumonia" |
Clinical Added Value
| no clinical added value |
Based on the current data available, MABELIO does not provide an improvement in actual benefit (IAB V, non-existent) in relation to the treatments currently used for managing hospital-acquired pneumonia, excluding ventilator-associated pneumonia. |
| Not applicable |
Community-acquired pneumonia : not applicable |
